London, United Kingdom – (The Hosting News) – September 28, 2006 – Web host and data management solutions firm, Phase Forward, will present at the UBS Global Life Sciences Conference at the Grand Hyatt in New York City.
The more than 28 presenting companies represent a variety of firms focused on the billion dollar biotechnology industry. Participating companies also include technology that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.
The Phase Forward presentation by Chief Executive Officer and President, Bob Weiler, and its Chief Financial Officer, Rodger Weismann, will be available in audio format by visiting the Investor section of the Company’s web site, for 30 days.
UBS is a wealth manager, top tier investment banking and securities firm, and a key global asset manager. In Switzerland, UBS is the market leader in retail and commercial banking. UBS, headquartered in Zurich and Basel, is present in all major financial centers worldwide. UBS’s financial businesses employ over 70,000 people worldwide.
Recently, Phase Forward reported that revenues for the second quarter of 2006 were $24.7 million, a 19% increase from $20.7 million in the second quarter of 2005. Within total revenue, InForm license, application hosting and other related revenues were $16.3 million, an increase of 19% from $13.7 million in the prior year period.
Phase Forward is a provider of integrated data management solutions for clinical trials and drug safety. The company offers solutions for electronic data capture (InForm), clinical data management (Clintrial), clinical trials signal detection (CTSD), strategic pharmacovigilance (WebVDME) and Signal Management), adverse event reporting (Clintrace) and applied data standards (WebSDM). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards.
Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 230 organizations and regulatory agencies worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, Food and Drug Administration, GlaxoSmithKline, Guidant, Merck, U.K. Medicines and Healthcare Products Regulatory Agency, National Institutes of Health, Procter and Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute and Serono.
To learn more, please visit: www.phaseforward.com.